Charles Russell Speechlys advises Kreos on growth capital investment in biotech company JenaValve Technologies, Inc.
Charles Russell Speechlys has advised Kreos Capital V (UK) Limited (“Kreos”) on its growth capital investment in JenaValve Technologies, Inc., a biotech company founded to develop next generation transcatheter aortic valve replacement systems for transapical and transfemoral implantation.
By virtue of its anatomically-based locator fixation and dual sealing valve design, the JenaValve Pericardial TAVR System is intended to enable ease of use, reduced risks of paravalvular regurgitation and need for permanent pacing, and durability of patient hemodynamic outcomes.
The Charles Russell Speechlys team was led by Corporate Legal Director Rossana Conti and comprised Banking Partner Daniel Sullivan and Banking Associate Roya Zohrabi. Our team worked in collaboration with Golenbock Eiseman Assor Bell & Peskoe LLP, a US law firm.
This deal further showcases the growing breadth and depth of our Life Sciences practice.
News & Insights
Could your esports business benefit from the Government’s new Future Fund?
Esports is an increasingly competitive industry not just in the UK but on a global scale - could it benefit from the new Future Fund?
Supreme Court decides that reflective loss rule does not bar claims made by unsecured creditors
A review of the recent Supreme Court judgment which significantly narrowed the scope of the rule against recovery of reflective loss.
Charles Russell Speechlys advises LiDCO Group plc on its £30m share premium account cancellation
LiDCO, a UK-based group manufactures and supplies invasive, minimally and non-invasive hemodynamic monitoring equipment.